Pharmacogenomics Pharmacogenomics. The accumulation of new information on various Biomarkers has propelled the field of Pharmacogenomics, which will bring about changes in the process of Drug Development. Genomics information will direct more personalized treatment regimens by identifying patients with genetic biomarkers who will be most likely to respond to a treatment and those who will respond adversely. Similarly, high-throughput genomic technologies will be increasingly used to identify Toxicology Biomarkers in Drug Development. Toxicology biomarkers will be crucial in identifying short-term and long-term genetic effects of drug-exposure. Currently, the use of Toxicology biomarkers is limited, but will play an important role in future clinical trials. The FDA is now encouraging Pharmaceutical industry to employ pharmacogenomics data in drug development to get a better understanding and reap the benefits of genomic analysis.   ASTRAGEN provides high-throughput Genomics and Proteomics analysis for Biomarkers in samples from Preclinical research and Clinical research studies. With a strong scientific background and peer-reviewed published papers on Genomics by our Team, we can design and perform Biomarker analysis for your clinical samples and make your results and data stronger and more amenable to approval by FDA.